Combination of NAD-like and non-NAD-like inhibitors was exceptionally effective in vitro and in vivo against BCR-ABL1-positive BRCA1-deficient CML in chronic phase, at the same time causing little or no toxicity to normal cells and tissues [72]. Here, BRCA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.